Crispr's Casgevy Launch: Promising Start, Uncertain Future

Bevan Goldswain/E+ via Getty Images Introduction Shares of CRISPR Therapeutics (NASDAQ:CRSP) have been on a rollercoaster ride as of late. I've been following the company closely for over a year now. Remember that CRISPR secured FDA approval last December for its gene therapy targeting sickle cell disease, Casgevy. On the same day, bluebird bio (BLUE), too, received the green light for its sickle cell gene therapy, Lyfgenia. My attitude toward CRISPR has always been cautious, even after Casgevy's groundbrea ...